Drug intelligence / Profile preview

Three Leaves

Development stage: Preclinical
Lead developer: The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Three Leaves is a pharmaceutical drug in tablet form being investigated for its hypoglycemic effects in healthy human subjects for the treatment of diabetes mellitus. It is currently in clinical development to evaluate its safety, pharmacokinetics, and pharmacodynamics.

Other names: 三叶片

Beyond the preview

Go deeper on Three Leaves.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Three Leaves.

Explore the full profile